CompletedInterventionalPhase 2Last updated Feb 19, 2010

A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, 5-Week Trial To Assess The Efficacy And Safety Of PD 0332334 Compared To Placebo And Alprazolam Extended-Release In Patients With Generalized Anxiety Disorder

Overview

ClinicalTrials.gov ID: NCT00921063
Lead Sponsor: PfizerINDUSTRY
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of PD 0332334 compared to placebo in the treatment of Generalized Anxiety Disorder in an adult population
Study Type: Interventional

Status

Overall Status: Completed
Start Date: Nov 2005
Primary Completion Date: Jul 2006Actual
Completion Date: Jul 2006Actual

Study Record Dates

First Submitted: Jun 15, 2009
First Submitted that Met QC Criteria: Jun 15, 2009
First Posted: Jun 16, 2009Estimated
Last Update Submitted that Met QC Criteria: Feb 17, 2010
Last Update Posted: Feb 19, 2010Estimated
Last Verified: Feb 2010

NCT00542685Completed

A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder

NCT00658762Terminated

A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)

NCT00658008Terminated

A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)

NCT00658372Terminated

A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)

NCT00735267Terminated

A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)

NCT00836069Terminated

Fixed Dose Study of PD 0332334 and Paroxetine for the Treatment of Generalized Anxiety Disorder